Biomea Fusion Initiated at Overweight by Capital One
Biomea Fusion's BMF-219: A Catalyst for Growth in Metabolic Disease Treatment and Oncology
Capital One Financial Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $25
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $22
Positive Week for Biomea Fusion, Inc. (NASDAQ:BMEA) Institutional Investors Who Lost 53% Over the Past Year
With 51% Institutional Ownership, Biomea Fusion, Inc. (NASDAQ:BMEA) Is a Favorite Amongst the Big Guns
Truist Financial Maintains Biomea Fusion(BMEA.US) With Hold Rating
Biomea Fusion (BMEA) Receives a Hold From Truist Financial
Biomea Fusion, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Biomea Fusion GAAP EPS of -$1.03
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $15
Buy Rating Affirmed for Biomea Fusion Amid Anticipated Clinical Advancements and Solid Financial Footing
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA), Stryker (SYK) and Teladoc (TDOC)
Express News | Biomea Fusion Inc : JP Morgan Cuts Target Price to $11 From $15
Earnings Flash (BMEA) BIOMEA FUSION Posts Q2 Loss $-1.03
Biomea Fusion | 10-Q: Q2 2024 Earnings Report
Express News | Biomea Fusion Inc: Announcement of Third Program in Obesity on Track for Q3 2024
Express News | Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
Express News | Biomea Fusion Q2 Net Income USD -37.276 Million